rs10865710 — PPARG PPARG C-681G

PPARG C-681G — The Promoter Dimmer Switch

PPARG¹¹ Full name: Peroxisome Proliferator-Activated Receptor Gamma — a nuclear receptor that controls adipocyte differentiation, fatty acid storage, and insulin sensitisation is the master regulator of fat-cell biology. Unlike the well-studied Pro12Ala coding variant (rs1801282), the C-681G variant (rs10865710) sits in the 5' regulatory region of the gene, roughly 681 base-pairs upstream of the transcription start site, in a region that functions as an active transcriptional enhancer²² Enhancers are non-coding DNA elements that bind transcription factors and dramatically amplify nearby gene expression.

The Mechanism

The variant lies within a functional enhancer element that binds the transcription factor CREB2³³ CREB2
CREB2 (also known as ATF4) is a stress-responsive transcription factor that activates gene expression by binding to CRE motifs in enhancer and promoter regions. Luciferase reporter assays demonstrated that the G allele reduces enhancer activity by approximately 29% compared to the reference C allele (0.068 ± 0.004 vs. 0.096 ± 0.002, P = 0.0005). This reduced transcriptional drive results in lower PPARγ protein levels in tissues that depend on the enhancer. Because PPARγ is the primary driver of insulin sensitisation in adipose tissue and the target of thiazolidinedione⁴⁴ Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone work by binding and activating PPARγ antidiabetic drugs, even a modest suppression of expression has downstream consequences for glucose disposal, lipid handling, and cardiovascular risk.

The Evidence

Lu et al. (2019)⁵⁵ Lu et al. (2019)
Lu H et al. Enhancer polymorphism rs10865710 associated with traumatic sepsis is a regulator of PPARG gene expression. Crit Care, 2019 provided the first mechanistic proof that rs10865710 is a functional regulatory variant — not merely a statistical association. In 797 Han Chinese trauma patients, the G allele was associated with sepsis susceptibility (OR 1.41, 95% CI 1.11–1.79, P = 0.004), replicated in a second cohort (OR 1.45, P = 0.046), and meta-analysed at OR 1.38 (95% CI 1.17–1.71, P < 0.0001). Crucially, genotype correlated directly with measured PPARγ expression levels (P = 9.2 × 10⁻⁵), establishing the regulatory mechanism.

For metabolic disease, Song et al. (2022)⁶⁶ Song et al. (2022)
Song Y et al. rs10865710 polymorphism in PPARG promoter is associated with the severity of type 2 diabetes mellitus and coronary artery disease in a Chinese population. Postgrad Med J, 2022 showed in 635 subjects that G allele carriers with T2DM had significantly elevated glucose, triglycerides, apolipoprotein B, and lipoprotein(a). Among CAD patients, G allele carriers had higher Gensini scores and more diseased coronary vessels, suggesting the variant tracks with metabolic and atherogenic burden.

Cao et al. (2012)⁷⁷ Cao et al. (2012)
Cao CY et al. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp Med, 2012 found the G allele was significantly more frequent in NAFLD patients (41.1%) than controls (34.8%, P = 0.03), and a haplotype carrying the G allele increased NAFLD susceptibility.

A Chinese Han case-control study (n = 1,106) by Zhang et al. (2017)⁸⁸ Zhang et al. (2017)
Zhang X et al. Gene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han Population. Oncotarget, 2017 reported an OR of 1.47 (95% CI 1.15–1.92) for CAD in homozygous GG carriers.

Practical Implications

The C allele (reference, no-change) predominates globally: ~56% of people are CC, 38% are CG, and 6% are GG. The G allele frequency is fairly uniform across ancestries (22–33%), meaning this variant does not exhibit the strong ancestry-stratification seen in some metabolic SNPs. For G allele carriers the key modifiable factors are those that most directly compensate for reduced PPARγ activity: dietary saturated fat load (which increases the demand on fat-cell storage and lipid clearance), triglyceride levels, and glucose control markers.

Interactions

rs10865710 acts synergistically with the Pro12Ala coding variant (rs1801282) in the same gene. Cecil et al. found opposing and interacting growth phenotypes when both variants were analysed together in children. A five-way gene-gene interaction including rs10865710 and SNPs in PPARD and PPARA was linked to abdominal obesity risk. As a promoter variant, rs10865710 is plausibly additive with rs1801282 — the coding variant changes receptor function while rs10865710 changes receptor abundance. Carriers of G at rs10865710 and CC (Pro/Pro) at rs1801282 combine lower PPARγ levels with a less efficient receptor, compounding metabolic disadvantage.